[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2592 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 2592
To require the Administrator of the Federal Aviation Administration to
publish the list of medications that the Administrator has compiled for
purposes of the medical certification of airmen, and for other
purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
April 2, 2025
Mr. Casten (for himself and Mr. Stauber) introduced the following bill;
which was referred to the Committee on Transportation and
Infrastructure
_______________________________________________________________________
A BILL
To require the Administrator of the Federal Aviation Administration to
publish the list of medications that the Administrator has compiled for
purposes of the medical certification of airmen, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Aviation Medication Transparency Act
of 2025''.
SEC. 2. LIST OF APPROVED MEDICATIONS.
(a) In General.--Not later than 1 year after the date of enactment
of this Act, the Administrator of the Federal Aviation Administration
shall publish and maintain on a publicly available website of the
Administration the list of medications and treatments that may be
safely prescribed to an airman to treat certain medical conditions that
the Administrator has compiled for purposes of the issuance of a
medical certification to an airman.
(b) Requirements.--The list required under subsection (a) shall--
(1) be drafted in consultation with--
(A) the Aeromedical Innovation and Modernization
Working Group;
(B) the certified exclusive bargaining
representatives of air traffic controllers of the
Administration certified under section 7111 of title 5,
United States Code;
(C) the principal organization representing the
largest certified collective bargaining representative
of airline pilots; and
(D) any other stakeholder determined relevant by
the task group, including any stakeholders described in
section 411(d)(3)(B) of the FAA Reauthorization Act of
2024;
(2) be comprehensive;
(3) be drafted in a user-friendly and accessible manner and
provided to airmen at the time when such airmen first seek a
license and medical certification;
(4) indicate what, if any, period of time, on average, an
airman must have limited or no duties to stabilize on an
approved medication;
(5) include the list of medications that the Administrator
has designated as ``Do Not Issue'';
(6) include a mechanism for doctors or medical providers to
contact the Federal Aviation Administration regarding questions
related to such list;
(7) include any additional information that the
Administrator determines is appropriate to provide with respect
to what conditions a certain medication may or may not be used
to treat and any information to explain why a medication is
allowed or prohibited by the Federal Aviation Administration;
and
(8) include any other information or clarification that the
Administrator determines appropriate.
(c) Annual Update.--Not later than 1 year after the date of
publication of the list required under subsection (a), and annually
thereafter, the Administrator shall update such list, as appropriate.
<all>